[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=6ef96b8921b65dc23526a99dc1099064a09f3363c9396ad2e2caf45042feb065",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747068300,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 134409182,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=6ef96b8921b65dc23526a99dc1099064a09f3363c9396ad2e2caf45042feb065"
    }
  },
  {
    "ts": null,
    "headline": "Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class",
    "summary": "Apogee Therapeutics, Inc. had promising results from its APG808 Phase 1b study show potential for every 2-month asthma treatment. Click for my APGE stock update.",
    "url": "https://finnhub.io/api/news?id=93dfdd92326403e6a9a5374d69056e7aed984616c946b2f4481040e03c54cd5e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747065865,
      "headline": "Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class",
      "id": 134391343,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205617501/image_2205617501.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Apogee Therapeutics, Inc. had promising results from its APG808 Phase 1b study show potential for every 2-month asthma treatment. Click for my APGE stock update.",
      "url": "https://finnhub.io/api/news?id=93dfdd92326403e6a9a5374d69056e7aed984616c946b2f4481040e03c54cd5e"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down",
    "summary": "Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% rise in 3 years.",
    "url": "https://finnhub.io/api/news?id=755ba2d8dd8f563078b1c1f1a7b8d20d163ea6c0c3b28c0f2aaa7ed9abf9adfd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747053314,
      "headline": "Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down",
      "id": 134386071,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412857430/image_1412857430.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% rise in 3 years.",
      "url": "https://finnhub.io/api/news?id=755ba2d8dd8f563078b1c1f1a7b8d20d163ea6c0c3b28c0f2aaa7ed9abf9adfd"
    }
  },
  {
    "ts": null,
    "headline": "Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet",
    "summary": "Trump aims to cut US drug prices by 30-80% via Executive Order. Check out how pharma companies could be affected and how this may play out in the future.",
    "url": "https://finnhub.io/api/news?id=f3bdfb278b3d923fb7ecd9a0eb0a6ca51ad748153503c12329641a35d2d60c57",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747053003,
      "headline": "Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet",
      "id": 134386076,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1756275584/image_1756275584.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Trump aims to cut US drug prices by 30-80% via Executive Order. Check out how pharma companies could be affected and how this may play out in the future.",
      "url": "https://finnhub.io/api/news?id=f3bdfb278b3d923fb7ecd9a0eb0a6ca51ad748153503c12329641a35d2d60c57"
    }
  },
  {
    "ts": null,
    "headline": "3 of Wall Street’s Favorite Stocks Skating on Thin Ice",
    "summary": "Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.",
    "url": "https://finnhub.io/api/news?id=72c7142cabfda7ba962c5745fb9af7a00046a99be0467d338898626e4e220094",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747024904,
      "headline": "3 of Wall Street’s Favorite Stocks Skating on Thin Ice",
      "id": 134379572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.",
      "url": "https://finnhub.io/api/news?id=72c7142cabfda7ba962c5745fb9af7a00046a99be0467d338898626e4e220094"
    }
  }
]